FDA Action on CMV Diagnostics Represents Important Advance for Testing Access

The U.S. Food and Drug Administration’s order changing the classification for tests used to measure cytomegalovirus loads in transplant patients is an important step in improving and making more accessible a critical tool for patient care management.

Groups Call for FDA to Maintain Independent Authority, Transparency in COVID-19 Vaccine Approvals

In a letter to U.S. Food and Drug Administration leaders today, more than 90 organizations representing physicians and other health providers, as well as scientists, patients and medical advocates, urge the agency to ensure that reviews of COVID-19 vaccine candidates meet all regulatory standards prior to authorization or licensure.

IDSA Launches COVID-19 Website for Frontline Clinicians with Support from CDC

With funding from the Centers for Disease Control and Prevention, the Infectious Diseases Society of America has launched the COVID-19 Real-Time Learning Network microsite. The site brings together the latest clinical guidance, institutional protocols, clinical trials data, practice tools and resources from a variety of medical subspecialties around the world.

Journal Supplement Highlights Need for Diversity in Building Future ID Workforce

A new collection of articles, now available online, highlights the critical importance of nurturing a diverse next generation of infectious diseases specialists and leaders.

The 75th United Nations General Assembly Opening Underscores Needs for Multilateral Health Responses

As the United Nations General Assembly opens for the first time in its 75-year history without an on-site gathering of world leaders, the critical need for international collaboration to end the current pandemic and prevent the next one should be clearer and more compelling than ever.

IDSA Releases Guidance On Treatment Of Antimicrobial-Resistant Infections

New guidance from the Infectious Diseases Society of America offers timely practice advice for the clinical treatment of three of the most common drug-resistant pathogens

Infectious Diseases and HIV Specialists Call for Urgent Policy Action to Reduce Harms of Injection Drug Use During the COVID-19 Pandemic

In a new policy paper, IDSA and HIVMA call for urgent action to reduce illness and death associated with the overlapping epidemics of injection drug use and infectious diseases, outlining key steps needed now more than ever during the COVID-19 pandemic.

Infectious Diseases Specialists to FDA: Don’t Cut Corners in COVID-19 Vaccine Approval

The Infectious Diseases Society of America and its HIV Medicine Association are urging the Food and Drug Administration to ensure rigorous safety and efficacy data support the approval of a COVID-19 vaccine before its widespread use by the public.  

IDSA/HIVMA Statement on Changes to CDC Guidance

IDSA and HIVMA call for the immediate reversal of the abrupt revision of the CDC COVID-19 testing guidelines which diminish the importance of testing asymptomatic individuals who were exposed to COVID-19.

As COVID-19 Cases Approach 5 Million in U.S., Infectious Diseases Leaders Call on White House for Unified Action on Masks

In a letter sent to Vice President Mike Pence today, leaders of the Infectious Diseases Society of America and its HIV Medicine Association are urging the White House to issue a strong federal directive calling for mask requirements in all states to curtail the spread of COVID-19 across this country, protect the economy and safely reopen schools.

Twenty-three Institutions Receive the IDSA Antimicrobial Stewardship Centers of Excellence Designation

One of IDSA’s top priorities is fighting antimicrobial resistance through research, education, training and policy initiatives. Our Centers of Excellence program honors institutions that have demonstrated leadership in that fight

IDSA, HIVMA Urge Inclusion of People Living with HIV in COVID-19 Clinical Trials

In a letter sent Wednesday to officials heading federal efforts to develop a vaccine against COVID-19, leaders of the Infectious Diseases Society of America and its HIV Medicine Association have urged that participation in clinical trials of vaccine candidates be open to people living with HIV.